India Pharma Outlook Team | Friday, 11 September 2026
Alembic Pharmaceuticals has delivered a clear compliance turnaround at its Vadodara bioequivalence facility.
The site moved from a procedural Form 483 observation and a warning letter linked to a clinical investigator to a clean, unannounced USFDA inspection that raised zero flags.
This sequence shows steady process correction and operational resilience across roughly 18 months rather than a single isolated success.
The latest zero-observation outcome also confirms that the corrective actions taken after the earlier findings have fully restored regulatory confidence in the facility.
In March 2025, the USFDA conducted a scheduled inspection at Alembic’s bioequivalence facility in Vadodara. The agency carried out the review from 3 March to 7 March. At the close of the inspection, the USFDA issued a Form 483 that contained one procedural observation.
Alembic informed exchanges that it would submit a comprehensive response within the stipulated period and restated its commitment to high quality standards and regulatory compliance.
Also Read: How Can Indian Pharma Strengthen Quality Amid Rising FDA Scrutiny
The same inspection cycle later produced further regulatory correspondence. The USFDA issued a Warning Letter to the clinical investigator associated with a bioequivalence study conducted at the Vadodara facility.
The letter addressed observations concerning the Informed Consent Form used in that study. Alembic clarified that the observations did not relate to data integrity. The company assessed that the warning letter imposed no restriction on the operations of the bioequivalence facility and coordinated with the clinical investigator to prepare an appropriate response within the required timeline.
The USFDA conducted an on-site bioequivalence inspection at the same Vadodara facility from 31 August 2026 to 10 September 2026. The inspection concluded with zero Form 483 observations.
Key steps in the compliance sequence include:
The clean outcome of the latest unannounced audit marks the end of the regulatory chapter that began with the procedural observations. Alembic’s Vadodara bioequivalence facility has therefore progressed from flagged findings to a zero-observation result, demonstrating that the corrective measures taken in the intervening period produced a measurable compliance turnaround.
